Story perspectives

Timing Immunochemotherapy Boosts Lung Cancer Survival Rates

2/7/2026

43 10

Summary

Story summary

A study led by Hunan Cancer Hospital and supported by the Chinese University of Hong Kong found that immunochemotherapy given before 3pm in advanced lung cancer doubled progression-free survival and increased overall survival by 70%.
The finding suggests adjusting treatment timing could boost efficacy without additional costs.
The study is the first randomized study to show timing's impact on outcomes.
Further research is needed to confirm these results.

1 of 1

Story summary

A study led by Hunan Cancer Hospital and supported by the Chinese University of Hong Kong found that immunochemotherapy given before 3pm in advanced lung cancer doubled progression-free survival and increased overall survival by 70%.
The finding suggests adjusting treatment timing could boost efficacy without additional costs.
The study is the first randomized study to show timing's impact on outcomes.
Further research is needed to confirm these results.